Endo International (ENDP) Downgraded by JPMorgan Chase & Co.

JPMorgan Chase & Co. downgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a neutral rating to an underweight rating in a research report sent to investors on Monday morning, 24/7 WallStreet reports. JPMorgan Chase & Co. currently has $9.00 price target on the stock.

Several other research analysts have also commented on the company. ValuEngine lowered Endo International from a hold rating to a sell rating in a research report on Wednesday, May 1st. BidaskClub upgraded Endo International from a sell rating to a hold rating in a research report on Tuesday, April 30th. Zacks Investment Research lowered Endo International from a hold rating to a strong sell rating in a research report on Tuesday, April 30th. Gabelli reiterated a hold rating on shares of Endo International in a research report on Wednesday, March 27th. Finally, SunTrust Banks began coverage on Endo International in a research report on Tuesday, March 19th. They issued a buy rating and a $13.00 target price for the company. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $14.88.

Shares of ENDP opened at $6.60 on Monday. The company has a market capitalization of $1.52 billion, a PE ratio of 2.28 and a beta of 1.12. Endo International has a 52 week low of $5.92 and a 52 week high of $18.50.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, May 9th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.42 by $0.11. The company had revenue of $720.00 million during the quarter, compared to analyst estimates of $692.31 million. Endo International had a negative return on equity of 199.18% and a negative net margin of 18.35%. The business’s revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.67 EPS. Research analysts expect that Endo International will post 2.2 earnings per share for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC grew its stake in shares of Endo International by 8.8% in the 1st quarter. Geode Capital Management LLC now owns 2,666,043 shares of the company’s stock valued at $21,407,000 after purchasing an additional 214,518 shares during the period. Factorial Partners LLC bought a new stake in shares of Endo International in the 1st quarter valued at approximately $193,000. Acadian Asset Management LLC grew its stake in shares of Endo International by 83,573.5% in the 1st quarter. Acadian Asset Management LLC now owns 771,470 shares of the company’s stock valued at $6,194,000 after purchasing an additional 770,548 shares during the period. Piedmont Investment Advisors Inc. grew its stake in shares of Endo International by 5.8% in the 1st quarter. Piedmont Investment Advisors Inc. now owns 50,737 shares of the company’s stock valued at $407,000 after purchasing an additional 2,795 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Endo International by 24.8% in the 1st quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,900,414 shares of the company’s stock valued at $15,260,000 after purchasing an additional 378,182 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: What is the Rule of 72?

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.